We serve Chemical Name:2-chloro-n,6-dimethyl-3-nitropyridin-4-amine CAS:182257-03-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-chloro-n,6-dimethyl-3-nitropyridin-4-amine
CAS.NO:182257-03-0
Synonyms:2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine
Molecular Formula:C7H8ClN3O2
Molecular Weight:201.61000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:70.74000
Exact Mass:201.03100
LogP:2.58950
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine Use and application,2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine technical grade,usp/ep/jp grade.
Related News: Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China. 2-chloro-n,6-dimethyl-3-nitropyridin-4-amine manufacturer Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China. 2-chloro-n,6-dimethyl-3-nitropyridin-4-amine supplier According to the 2013-2018 New Drug Review Summary report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years. 2-chloro-n,6-dimethyl-3-nitropyridin-4-amine vendor Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 2-chloro-n,6-dimethyl-3-nitropyridin-4-amine factory Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.
